PPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
The US FDA conducted a Good Manufacturing Practices (GMP) inspection at Piramal Pharma's Sellersville, USA facility from 4th to 8th May, 2026. At the conclusion of the inspection, the US FDA issued a Form-483 with three observations. The inspectors classified the observations under VAI (Voluntary Action Indicated), which is the milder classification indicating voluntary action is needed rather than official enforcement. Importantly, none of the observations relate to data integrity concerns. The company is preparing a detailed response to address all observations and will submit it to the US FDA within stipulated timelines.
The VAI classification is relatively benign and does not indicate a critical compliance failure. However, investors should monitor the company's response and any further FDA communications, as unresolved observations could eventually lead to regulatory action affecting the facility's operations or product approvals.